Professor Gustav GAUDERNACK (2003)
Prof. Gustav Gaudernack is Head of the vaccine development
program at the Norwegian Radium Hospital (DNR) and also
the head of Section for Immunotherapy at DNR. He presently
holds a 3-year visiting professorship in immunotherapy
at the University of Bern.
He is a member of the EORTC biological trials development
group (BTDG) and the International Cooperative Group
on Hereditary Non Polyposis Cancer (ICG-HNPCC). Member
Advisory Board, Biological Therapy of Cancer-From Disease
to Target-oriented Therapy (EORTC/NCI), and Scientific
Committee International Society for Cancer Gene Therapy
Singapore Meeting). Member of Advisory Board on Peptide
Vaccine Approaches, Merck KGaA (until 2001), Advisory
Board Centocor GenVax program, Advisory Board DYNAL
Biotec: Immunosystems. Advisory Board GemVax AS, Member
Scientific Panel for Biotherapy Development Association
and Member ISHAGE Immunotherapy & Dendritic Cells
Prof. Gaudernack has published 170 research articles
in international journals, mostly on cancer immunology,
and holds 13 different patents in the field of cancer
diagnostics and cancer vaccines. Based on the discovery
of a number of new cancer tumor antigens, he has organized
and participated in a large number of investigator initiated
and industry sponsored clinical trials of tumor vaccines.
These trials include the first study of a ras peptide
vaccine (1993) and the first study of telomerase peptide
vaccination in cancer patients (2000), two immuno-gene
therapy trials with mRNA transfected dendritic cells.
He is currently engaged in the planning of the first
prophylactic cancer vaccine trial designed to prevent
an inherited form of cancer due to defects in the mismatch
repair machinery leading to colon and endometrial cancer.